<DOC>
	<DOCNO>NCT00994890</DOCNO>
	<brief_summary>This study investigate safety three fix dose level tanezumab ( 2.5 mg , 5 mg , 10 mg ) administer 8-week interval subcutaneous injection multiple ( 7 ) time study treatment period .</brief_summary>
	<brief_title>A Long Term Study Safety Tanezumab When Administered By Subcutaneous Injections</brief_title>
	<detailed_description>Safety study tanezumab relief osteoarthritis pain This study terminate 6 December 2010 follow US FDA clinical hold tanezumab osteoarthritis clinical study halt dose enrollment patient 23 June 2010 potential safety issue .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<criteria>Osteoarthritis knee hip base American College Rheumatology criterion radiographic ( X ray ) confirmation ( Kellgren Lawrence xray grade â‰¥2 ) ; Body mass index ( BMI ) &gt; 39 kg/m2 ; Pregnancy intent become pregnant Planned surgical procedure duration study History clinically significant cardiovascular , central nervous system psychiatric disease Previous exposure exogenous NGF anti NGF antibody ; Use biologics study medication , Live liveattenuated intranasal vaccine ( eg , Flumist ) , allowable exception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Double-blind safety</keyword>
</DOC>